German Cohort Data

Stefan Mauss

Centre for HIV and Hepatogastroenterology

Duesseldorf

Germany

EUROPEAN HIV HEPATITIS CO-INFECTION (EHHC)

CONFERENCE

Dr Stefan Mauss

Center for HIV and Hepatogastroenterology, Düsseldorf, Germany

COMPETING INTEREST OF FINANCIAL VALUE ≥ £1,000:	
Speaker Name	**Statement**
Stefan Mauss	Adboard: AbbVie, BMS, Gilead, MSD, ViiV Speaker: AbbVie, BMS, Gilead, Janssen Grant: Gilead
Date	26th November 2015

German C Cohort (GECCO)

Genotype distribution (n=1157)



Treatment regimen



Characteristics of cohort (medians and IQR) – GT1 and GT4

	HCV	HIV/HCV
Number of patients	685	215
male	375 (55%)	194 (90%)
age (years)	55 (47 – 63)	48 (42 – 53)
baseline HCVRNA (IU/mL)	1.2 $x10^6$ (0,4 $x10^6$-2.9 $x10^6$)	1.3 $x10^6$ (0.28 $x10^6$-3.7 $x10^6$)
baseline ALT (IU/mL)	64 (42 - 107	67 (43 – 130)
baseline HIVRNA <20 copies/mL		176/201 (88%)
baseline CD4+ cells/µL		614 (406 – 784)
cirrhosis	186 (27%)	28 (13%)
Opioid substitution	125 (18%)	41 (19%)
GT 1	656 (96%)	173 (81%)
GT 4	29 (4%)	42 (19%)
Sofosbuvir+peginterferon+ribavirin	77 (11%)	48 (22%)
Sofosbuvir+daclatasvir	92 (13%)	29 (14%)
Sofosbuvir+simeprevir	31 (5%)	6 (3%)
Sofosbuvir+ledipasvir	385 (56%)	117 (54%)
Paritaprevir+ombitasvir+dasabuvir (3D)	92 (13%)	8 (3%)

Mauss et al. AASLD 2015, P1156

Viral response according to treatment regimen



SOF+PegIFN+RBV n=125	111	119	117
SOF+DCV +/-RBV n=121	108	115	112
SOF+SMV +/-RBV n=37	31	34	34
SOF+LDV +/-RBV n=502	317	302	222
3D=DSV/OBV/PTV/r +/-RBV n=100	72	50	30

Mauss et al. AASLD 2015, P1156

SVR according to HIV status
(p=0.096)



HCV n=685	470	381
HCV/HIV n=215	129	98

Mauss et al. AASLD 2015, P1156

SVR12 according to HIV-status and HCV-therapy



HCV n=	70	86	29	192	48
HCV/HIV n=	47	26	5	30	2
p=	0.365	0.622	-	0.668	-

data on file

SOF/PegIfn/RBV vs SOF/DCV+SOF/SMV/+SOF/LDV (**p<0.01)



SOF/PegIFN/RBV n=	119	117
SOF/DCV+SOF/SMV/+SOF/LDV n=	451	368

data on file

Liver cirrhosis is the most important predicor of treatment failure

Viral response according to APRI score
APRI ≤ 1 non-cirrhotic; APRI > 2 cirrhosis (p=0.012)



non-cirrhotic n=601	401	395	299
Cirrhosis n=123	96	90	79

Viral response according to clinical cirrhosis status (p=0.013)



non-cirrhotic n=476	437	446	339
cirrhosis n=214	96	93	89

Mauss et al. AASLD 2015, P1156

Shortening therapy with SOF/LDV to 8 weeks

SVR 4 in subgroups



SVR12 in subgroups



Christensen et al. AASLD 2015, P1081

Shortening therapy with SOF/LDV to 8 weeks

Figure 6: Viral response according to SOF/LDV treatment duration (8 versus 12 weeks)



8 weeks therapy n=162	112	83
12 weeks therapy n=313	179	133

Mauss et al. AASLD 2015, P1156

Is GT 2 really easy to treat?

DHC-R
Deutsches Hepatitis C-Register

SVR12 in SOF+RBV for 12 weeks in GT2 (n=263)



A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. Kalinina O[1], Norder H, Mukomolov S, Magnius LO. J Virol. 2002 Apr;76(8):4034-43.

Data on file

Acknowledgement

- **Berlin**: A Baumgarten, P Ingiliz
- **Bonn**: C Boesecke, JK Rockstroh
- **Duesseldorf**: S Mauss, G Schmutz
- **Frankfurt**: T Lutz
- **Hamburg**: K Schewe
- **Herne**: D Hueppe
- **Leverkusen:** KG Simon
- **Muenster**: S Christensen, H Busch

Principal Investigator
D Hueppe

CEO
H Wedemeyer

Management Board

P Buggisch, M Cornberg, M Manns, S Mauss, C Niederau, C Sarrazin, P Schirrmacher, S Zeuzem